Less than 10% of individuals who could benefit from weight-loss injections including Wegovy have access to them, caution the World Health Organization as it issues its initial recommendations on the therapies.
Given in excess of 1,000,000,000 people worldwide now obese, it is calling for increased and just availability to this class of drugs.
Per estimates, in excess of 2,000,000,000 will be obese by 2030 if no action is taken.
"The latest guidelines acknowledges that obesity is a chronic disease that can be addressed with thorough and continuous treatment," stated the agency's head Tedros Adhanom Ghebreyesus.
Significant expense, constrained manufacturing, and distribution challenges are key obstacles to universal availability to the injections that can assist patients in reducing substantial body mass, notes the organization.
Weight-Loss Drug Supply Crisis
Even under the current best projected case, the production of these medications could only cover about 100 million people – less than 10% of the global need, per the health organization.
The advice encourages governments and firms to increase availability, through strategies including licensing agreements.
A patent on a key compound – the primary ingredient of a leading brand – is set to lapse in several countries in 2026.
The Way Obesity Jabs Function
GLP-1 drugs replicate a body's own hormone to delay gastric emptying, reduce hunger and enhance the sense of being full so people consume fewer calories.
People typically see weight reduction within a few weeks of commencing the weekly injections.
Evidence suggests people may put most of the weight back on within a year of halting the drug, as their typical hunger resume.
To be overweight or obese increases your chance for experiencing health problems, including diabetes, heart disease, brain attack, and some malignancies.
Obesity affects individuals in all nations and was responsible for 3.7 million fatalities worldwide in 2024, per the WHO.
